Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Developments in neoadjuvant immunotherapy options for early-stage lung cancer patients

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 172

Dr Luis Raez - Memorial Healthcare System, Hollywood, USA

Dr Luis Raez speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about exciting developments in lung cancer treatments from this year's meeting.

Dr Raez also provides his insight into the exciting developments in lung cancer treatment featured in this year's meeting, including the update on the LCMC study which uses atezolizumab both in the neoadjuvant and adjuvant setting.

Dr Raez also speaks about the results from the NEOSTAR trial, which combined immunotherapeutic agents nivolumab and ipilimumab in the neoadjuvant setting.

Dr Raez said the development of neoadjuvant options for early-stage lung cancer patients, as well as trials combining immunotherapy with chemotherapy, provides a very promising landscape for the future of lung cancer treatments.

Categories:

· ASCO 2019

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation